High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable ...

Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

If you or a loved one has been diagnosed with BCG-unresponsive non-muscle invasive bladder cancer and are exploring your ...

The FDA approved a gemcitabine intravesical system (Inlexzo) for adults with non-muscle-invasive bladder cancer (NMIBC), the agency announced on Tuesday. The indication for the chemotherapy-containing ...

Credit: J&J. The New Drug Application is supported by data from cohort 2 of the single-arm, phase 2b SunRISe-1 study. The device remains in the bladder and provides a sustained release of gemcitabine ...

SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic complete response in patients with MIBC ineligible for or refusing ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

The American Urological Association (AUA) most recently published guidelines on the management of NMIBC in 2007. 19 These 2007 AUA guidelines set out to address questions only when there was ...

Itay: Researchers have found in a new study that a single postoperative dose of Mitomycin C significantly reduces early ...